Rhythm Pharmaceuticals stock closed up 2.9% at US$105.78, a sharp intraday vote of confidence after a choppy month that left the shares down about 7% over 30 days. The move came as investors digested a Q2 report that paired rapid revenue expansion with continued losses, a familiar trade off in high growth biotech.

The headline this quarter is clear. Global net product sales reached US$71.3 million, powered by early demand for IMCIVREE in acquired hypothalamic obesity, while the company still reported a net loss of US$50.4 million. The central issue for investors is how long that level of growth can support the company’s path toward profitability.

Love the rapid IMCIVREE revenue ramp at Rhythm Pharmaceuticals but concerned about the ongoing losses and cash burn risk? Take a look at our 84 resilient stocks with low risk scores.

Q2 2026 Earnings Summary

• Total Revenue (Q2 2026 vs Q2 2025): US$71.3 million vs. US$48.5 million (strong year on year increase in quarterly revenue)
• Net Loss, Excl. Extra Items (Q2 2026 vs Q2 2025): loss of US$50.4 million vs. loss of US$48.0 million (year on year widening of quarterly net loss)
• Basic EPS (Q2 2026 vs Q2 2025): loss of US$0.73 per share vs. loss of US$0.75 per share (slight year on year improvement in quarterly loss per share)
• Pipeline Breadth, Late Stage (TTM to Q4 2025 vs not disclosed prior): 6 products in Phase III and 2 products in Phase II in the trailing twelve months to Q4 2025 (indicates a broad late stage development portfolio for Rhythm Pharmaceuticals)

Tired of scrolling through dense earnings releases and rows of biotech figures? View Rhythm Pharmaceuticals’ full story in a clear visual format that highlights its revenue trends and growth profile using the company report for Rhythm Pharmaceuticals.

Rhythm bull case: HO launch and pipeline on trial

Bulls argue Rhythm Pharmaceuticals can turn IMCIVREE and next generation MC4R agonists into a durable rare obesity franchise with growing patient volume and extended exclusivity. Q2 gives some support. Net product sales reached US$71.3 million, helped by acquired hypothalamic obesity where more than 400 start forms from about 300 prescribers and over 20% writing repeat scripts point to early breadth and depth of adoption. A more than 20% quarter on quarter increase in reimbursed patients shows the commercial engine can convert that interest into treated patients. RM-718 Phase II data with 11.6% mean BMI reduction at Week 16 and no generalized hyperpigmentation, plus patents past 2040, help the narrative that Rhythm can refresh the franchise beyond setmelanotide. The HO publication in NEJM and FDA approval in March 2026 also meet key de-risking milestones that bulls have been watching.

Rhythm bear case: concentration, losses and sustainability

Bears focus on Rhythm Pharmaceuticals’ reliance on setmelanotide, ongoing losses and the risk that revenue quality looks better than underlying profitability. Q2 does not remove those worries. The company reported a net loss of US$50.4 million despite US$71.3 million of revenue and an improving gross to net of 86%. That supports the concern that operating expense intensity remains high and that cash burn could eventually require new capital even with a stated 24+ month runway. Setmelanotide still drives the entire commercial story, with US$51 million from the U.S. and the rest tied to early international markets that remain dependent on reimbursement decisions. Ex U.S. revenue fell to US$20.3 million after a French “contribution M” charge, which shows how pricing rules can swing reported performance. Two discontinuations in the RM-718 trial also remind you that pipeline execution risk is very much live.

Compare Rhythm Pharmaceuticals’ operational momentum with what the Street is signaling on future upside by checking where analyst targets sit versus the recent post earnings move in the stock. See the consensus price target analysis for Rhythm Pharmaceuticals to gauge how closely forecasts line up with the current HO launch and pipeline expectations.

Stay Ahead With Rhythm Pharmaceuticals

If the mix of rapid IMCIVREE revenue growth and ongoing losses at Rhythm Pharmaceuticals has your attention, register for free with Simply Wall St and add the stock to your Watchlist to track share price against fair value and wait for an entry point that matches your risk tolerance. Once you own shares, use the Portfolio Command Center to cut through daily noise and focus on key alerts across earnings, balance sheet changes and analyst revisions. For a broader view, tap into crowd insights and different investment angles through the Community. This approach can help you identify potential catalysts and risks early so you can stay informed rather than reacting after the fact.

Seeking Alternatives Beyond Rhythm Pharmaceuticals?

Fresh stock ideas do not stay under the radar for long. Spot potential breakout stories and momentum pockets before the crowd catches on. The window narrows quickly, act now.

• Spot potential cash generative compounders early by scanning a curated 52 high quality undervalued stocks that may still be flying under most investors’ radars.
• Ride structural demand shifts in materials by reviewing a hand picked set of 8 top copper producer stocks that could benefit if interest swings back toward critical metals.
• Target resilience first by filtering through 84 resilient stocks with low risk scores that aim to balance solid fundamentals with lower historical risk scores before conditions change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.